Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up

Abstract

Anti-p53 autoantibody is not related to clinical parameters of CRC and has no prognostic significance in long-term follow-up.

Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer

“…Furthermore, Yamaguchi et al (4) reported that other factors, including tumor location, histology, depth of tumor invasion, vessel invasion, distant metastasis, CEA and recurrence, were also significantly associated with positive Ap53Ab expression. Other studies (9,10) reported that no significant correlation was observed between positive Ap53Ab expression and clinicopathological factors. In the present study, several factors, including depth of tumor invasion, lymph node metastasis, stage and CEA, were found to be significantly associated with positive Ap53Ab expression.…”

“…Although previous reports (8,23) demonstrated that positive Ap53Ab expression was associated with poor prognosis in CRC patients, there appears to be no consensus (4,6,10). Recently, Yamaguchi et al (4) reported that no association between Ap53Ab expression and OS was found in 1384 CRC patients, although Ap53Ab expression was associated with relapse-free survival in 1212 CRC patients who underwent curative surgery.…”

“…These reports suggested that the measurement of Ap53Ab was useful for the screening of CRC patients with early-stage (stage 0 and I) disease, as the positive rate of Ap53Ab expression was higher compared with that of CEA and CA19-9. However, a consensus on the correlation between Ap53Ab expression and poor survival rate was not obtained (4,8,10). The aim of the present study was to investigate the positive rate and clinical significance of Ap53Ab expression in 674 CRC patients, and elucidate the association between Ap53Ab expression and survival.…”

Prognostic Value of Pre- and Postoperative Anti-p53 Antibody Levels in Colorectal Cancer Patients: A Retrospective Study

“…p53 Ab levels are elevated in 13-47% of preoperative CRC patients [5,6,7,8,9,10], as well as in patients with other solid tumors, such as in 11.2-32% of gastric cancer patients [12,16,17,18], 13.2-21.5% of breast cancer patients [34,35,36], 8-30% of lung cancer patients [13,19,20,21,22], and 7-32% of hepatocellular carcinoma patients [15,24,25,26,27]. In the present study, the percentage of CRC patients with p53 Ab elevation was 26.3%, corroborating previous reports (table 1).…”

“…p53 Ab production is associated with TP53 gene mutation in CRC tissue and the consequent accumulation of mutant TP53 protein. The p53 Ab can be found in 13-47% of CRC patients [5,6,7,8,9,10], and its elevation has been reported in a wide variety of solid cancers such as esophageal, gastric, lung, ovarian, and hepatocellular cancers [11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27]. Thus, the clinical applicability of the p53 Ab in cancer screening is well established.…”